Advertisement

Archives of Dermatological Research

, Volume 311, Issue 1, pp 63–69 | Cite as

Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?

  • Kamran Balighi
  • Maryam Daneshpazhooh
  • HamidReza Mahmoudi
  • Mehrnoosh Badakhsh
  • Amir Teimourpour
  • Amir Houshang Ehsani
  • Arghavan Azizpour
  • Zahra Akbari
  • Mostafa Mahdavinia
  • Mojtaba Ghasemiadl
  • Soheil TavakolpourEmail author
Original Paper
  • 87 Downloads

Abstract

During the last decade, successfully treatment of patients diagnosed with pemphigus vulgaris (PV) with rituximab (RTX) was reported by several authors. The present study has been designed to compare the clinical outcomes and RTX-related side effects between the two groups of early treated (≤ 6 months) and lately treated PV (> 6 months) patients with RTX. We did a retrospective study between Oct 2014 and Jun 2016 to compare the short-term efficacy and safety of RTX in PV diagnosed patients. The primary and secondary endpoints were complete/partial remission of disease and safely tapering of corticosteroids without disease relapse, respectively. Among the 250 RTX exposed PV patients in the selected period, 107 were successfully followed for the mean 19.71 ± 16.78 months. Twenty-four and eighty three have categorized as the early (≤ 6 months after diagnosis) or lately (> 6 months after diagnosis) RTX-treated patients, respectively. A higher rate of complete remission, longer time lasting remission phase, and a lower number of adjuvants were associated with early RTX treatment. Early treatment with RTX might be associated with improvement of clinical effects, but does not seems to be safer than lately RTX therapy. Those in the early treated group may not only have a higher chance to achieve complete remission, but also experience a longer time of disease remission with lower cumulative doses of adjuvant therapy.

Keywords

Pemphigus Rituximab Anti-desmoglein Autoimmune bullous disease 

Notes

Funding

There is no funding source.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study approved by research ethics committees in the Tehran University of Medical Sciences.

References

  1. 1.
    Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, Joly P (2009) ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 145:529–535.  https://doi.org/10.1001/archdermatol.2009.9 CrossRefGoogle Scholar
  2. 2.
    Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS (2016) First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. Int Immunopharmacol 34:25–31.  https://doi.org/10.1016/j.intimp.2016.02.013 CrossRefGoogle Scholar
  3. 3.
    Anandan V, Jameela WA, Sowmiya R, Kumar MMS, Lavanya P (2017) Rituximab: a magic bullet for pemphigus. J Clin Diagn Res 11:WC01–WC06.  https://doi.org/10.7860/JCDR/2017/21868.9717 Google Scholar
  4. 4.
    Balighi K, Sakhi RS, Daneshpazhooh M, Mahmoudi H, Teimourpour A, Tavakolpour S (2018) Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatol Ther.  https://doi.org/10.1111/dth.12671 Google Scholar
  5. 5.
    Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P (2007) Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 143:1033–1038.  https://doi.org/10.1001/archderm.143.8.1033 CrossRefGoogle Scholar
  6. 6.
    Di Zenzo G, Amber KT, Sayar BS, Muller EJ, Borradori L (2016) Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol 38:57–74.  https://doi.org/10.1007/s00281-015-0541-1 CrossRefGoogle Scholar
  7. 7.
    Feldman RJ (2015) Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol 173:858–859.  https://doi.org/10.1111/bjd.13823 CrossRefGoogle Scholar
  8. 8.
    Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, Ortonne N, Hue S, Paul M, Wolkenstein P, Chosidow O (2015) First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol 151:200–203.  https://doi.org/10.1001/jamadermatol.2014.2421 CrossRefGoogle Scholar
  9. 9.
    Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard M-A, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389:2031–2040.  https://doi.org/10.1016/S0140-6736(17)30070-3
  10. 10.
    Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS (2012) Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 148:1031–1036.  https://doi.org/10.1001/archdermatol.2012.1522 CrossRefGoogle Scholar
  11. 11.
    Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, Gilbert D, Dutot I, Roujeau JC, D’Incan M, Bedane C, Tron F, Joly P (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128:2859–2869.  https://doi.org/10.1038/jid.2008.178 CrossRefGoogle Scholar
  12. 12.
    Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP (2008) Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 58:1043–1046.  https://doi.org/10.1016/j.jaad.2008.01.012 CrossRefGoogle Scholar
  13. 13.
    Pollmann R, Schmidt T, Eming R, Hertl M (2018) Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol 54:1–25.  https://doi.org/10.1007/s12016-017-8662-z CrossRefGoogle Scholar
  14. 14.
    Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittorio C, Werth BB, Williams EA, Taylor L, Troxel AB, Werth VP (2009) Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 129:2404–2410.  https://doi.org/10.1038/jid.2009.72 CrossRefGoogle Scholar
  15. 15.
    Sharma VK, Bhari N, Gupta S, Sahni K, Khanna N, Ramam M, Sethuraman G (2016) Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol 82:389–394.  https://doi.org/10.4103/0378-6323.174379 CrossRefGoogle Scholar
  16. 16.
    Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147–1150.  https://doi.org/10.1182/blood-2007-12-129262 CrossRefGoogle Scholar
  17. 17.
    Tavakolpour S (2017) Current and future treatment options for pemphigus: is it time to move towards more effective treatments? Int Immunopharmacol 53:133–142.  https://doi.org/10.1016/j.intimp.2017.10.027 CrossRefGoogle Scholar
  18. 18.
    Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M (2018) Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol 54:131–138.  https://doi.org/10.1016/j.intimp.2017.11.005 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kamran Balighi
    • 1
  • Maryam Daneshpazhooh
    • 1
  • HamidReza Mahmoudi
    • 1
  • Mehrnoosh Badakhsh
    • 1
  • Amir Teimourpour
    • 1
  • Amir Houshang Ehsani
    • 1
  • Arghavan Azizpour
    • 1
  • Zahra Akbari
    • 1
  • Mostafa Mahdavinia
    • 1
  • Mojtaba Ghasemiadl
    • 1
  • Soheil Tavakolpour
    • 1
    Email author
  1. 1.Autoimmune Bullous Diseases Research Center, Razi HospitalTehran University of Medical SciencesTehranIran

Personalised recommendations